Twist Bioscience Corporation (NASDAQ:TWST) Director Keith Crandell purchased 75,000 shares of the stock in a transaction dated Friday, November 2nd. The shares were acquired at an average price of $14.00 per share, with a total value of $1,050,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Shares of NASDAQ:TWST opened at $15.83 on Wednesday. Twist Bioscience Corporation has a one year low of $12.38 and a one year high of $16.11.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://weekherald.com/2018/11/07/twist-bioscience-corporation-twst-director-keith-crandell-purchases-75000-shares-of-stock.html.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Featured Article: Do closed-end mutual funds pay dividends?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.